Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | November 19, 2019 | November 21, 2019 |
| INCYTE CORPINCY · Entity 3182 | President, Global Head of R&D | September 15, 2026 | September 17, 2026 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | February 01, 2023 | February 01, 2023 |
| TURMERIC ACQUISITION CORP.TMPM · Entity 139875 | Director | October 15, 2020 | October 15, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date November 19, 2019 · Filed November 21, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-19 · Exercise / conversion · Acquired 7,500 · Balance 7,500 Row 2 · 2019-11-19 · Sale · Disposed 7,500 · Balance 0 F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2025-11-04 | Direct | 63,833 |
Reported balance
After 2019-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-19 · Exercise / conversion · Disposed 7,500 · Balance 63,833 F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.
INCYTE CORP
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,157 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 2,957 · Balance 186,157 |
| Common StockSEC Table I · non-derivative | Direct | 190,708 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Exercise / conversion · Acquired 4,551 · Balance 190,708 |
| Common StockSEC Table I · non-derivative | Direct | 197,185 |
Reported balance
After 2026-09-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Acquired 6,477 · Balance 197,185 |
| Common StockSEC Table I · non-derivative | Direct | 206,418 |
Reported balance
After 2026-09-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-15 · Exercise / conversion · Acquired 9,233 · Balance 206,418 |
| Common StockSEC Table I · non-derivative | Direct | 197,185 |
Reported balance
After 2026-09-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-15 · Sale · Disposed 9,233 · Balance 197,185 |
| Common StockSEC Table I · non-derivative | Direct | 183,200 |
Reported balance
After 2026-09-15 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-09-15 · Sale · Disposed 13,985 · Balance 183,200 F1: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.76 · Expires 2033-07-13 | Direct | 4,225 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 2,957 · Balance 4,225 F2: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.18 · Expires 2034-01-17 | Direct | 4,551 |
Reported balance
After 2026-09-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-15 · Exercise / conversion · Disposed 4,551 · Balance 4,551 F3: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.25 · Expires 2034-07-14 | Direct | 20,356 |
Reported balance
After 2026-09-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-15 · Exercise / conversion · Disposed 6,477 · Balance 20,356 F4: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.93 · Expires 2035-01-16 | Direct | 18,466 |
Reported balance
After 2026-09-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-15 · Exercise / conversion · Disposed 9,233 · Balance 18,466 F5: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F2: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F3: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
F4: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
F5: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
Rubius Therapeutics, Inc.
Report date February 01, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,082 |
Reported balance
After 2023-02-01 transaction · row 1
1 source rowRow 1 · 2023-02-01 · Sale · Disposed 8,448 · Balance 66,082 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
TURMERIC ACQUISITION CORP.
Report date October 15, 2020 · Filed October 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-15 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249099) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-04 · Disposition to issuer · Disposed 141,011 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,233 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 10 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,466 Underlying: Common Stock · 9,233 shares Expires 2035-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,477 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 9 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,356 Underlying: Common Stock · 6,477 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,551 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 8 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,551 Underlying: Common Stock · 4,551 shares Expires 2034-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,957 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · derivative · entry 7 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,225 Underlying: Common Stock · 2,957 shares Expires 2033-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 13,985 | $120.49 | $1,685,052.65 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 6 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,200 F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 9,233 | $120.50 | $1,112,576.50 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,185 Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 9,233 | $71.93 | $664,129.69 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 6,477 | $64.25 | $416,147.25 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 4,551 | $61.18 | $278,430.18 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,957 | $61.76 | $182,624.32 |
DisclosureSEC source: 0001205703-26-000030 · wk-form4_1789675474.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 21:15 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,801 | $125.56 | $1,356,173.56 |
DisclosureSEC source: 0001205703-26-000028 · wk-form4_1787260512.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,200 F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,803 | $120.04 | $1,296,792.12 |
DisclosureSEC source: 0001205703-26-000027 · wk-form4_1786737658.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,001 F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 20:02 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 10,640 | $122.69 | $1,305,421.60 |
DisclosureSEC source: 0001205703-26-000025 · wk-form4_1786132939.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,804 F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:04 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,888 | $119.70 | $1,901,793.60 |
DisclosureSEC source: 0001205703-26-000023 · wk-form4_1785873861.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 215,444 F1 · balance_after: This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 57,861 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,861 Underlying: Common Stock · 57,861 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 33,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · derivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,508 Underlying: Common Stock · 33,508 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 13,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000021 · wk-form4_1784578174.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,332 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:08 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 4,950 | $115.09 | $569,695.50 |
DisclosureSEC source: 0001205703-26-000019 · wk-form4_1784232493.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,929 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 169,797 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:08 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 17,969 | $114.88 | $2,064,278.72 |
DisclosureSEC source: 0001205703-26-000019 · wk-form4_1784232493.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,879 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:58 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 25,469 | $95.59 | $2,434,581.71 |
DisclosureSEC source: 0001205703-26-000017 · wk-form4_1780520307.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,848 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 213,078 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| May 06, 2026 Filed May 20, 2026 20:01 UTC Amendment | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 31,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000015 · wk-form4a_1779307294.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,317 F1 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on May 6, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · shares: This Form 4/A amends the original Form 4, filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026 relating to the achievement of the performance criteria, which superseded the Compensation Committee's initial determination on April 15, 2026. F3 · balance_after: Including this certification of performance shares, this includes an aggregate of 261,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,590 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0001205703-26-000012 · wk-form4_1776802145.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,699 Underlying: Common Stock · 12,590 shares Expires 2035-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,077 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0001205703-26-000012 · wk-form4_1776802145.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,833 Underlying: Common Stock · 6,077 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 18,667 | $96.50 | $1,801,365.50 |
DisclosureSEC source: 0001205703-26-000012 · wk-form4_1776802145.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 262,692 F1 · balance_after: This includes an aggregate of 257,553 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 12,590 | $71.93 | $905,598.70 |
DisclosureSEC source: 0001205703-26-000012 · wk-form4_1776802145.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 6,077 | $64.25 | $390,447.25 |
DisclosureSEC source: 0001205703-26-000012 · wk-form4_1776802145.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 27,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001205703-26-000010 · wk-form4_1776456771.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, Global Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,692 F1 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 257,553 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,501 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0001205703-26-000008 · wk-form4_1773951619.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,910 Underlying: Common Stock · 11,501 shares Expires 2034-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,166 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0001205703-26-000008 · wk-form4_1773951619.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,102 Underlying: Common Stock · 7,166 shares Expires 2034-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:20 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 18,667 | $94.24 | $1,759,178.08 |
DisclosureSEC source: 0001205703-26-000008 · wk-form4_1773951619.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,800 F1 · balance_after: This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 11,501 | $64.25 | $738,939.25 |
DisclosureSEC source: 0001205703-26-000008 · wk-form4_1773951619.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 20:20 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 7,166 | $61.18 | $438,415.88 |
DisclosureSEC source: 0001205703-26-000008 · wk-form4_1773951619.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,575 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0001205703-26-000006 · wk-form4_1771880710.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,268 Underlying: Common Stock · 5,575 shares Expires 2034-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,093 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001205703-26-000006 · wk-form4_1771880710.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,182 Underlying: Common Stock · 13,093 shares Expires 2033-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 18,668 | $100.91 | $1,883,787.88 |
DisclosureSEC source: 0001205703-26-000006 · wk-form4_1771880710.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 234,800 F1 · balance_after: This includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 5,575 | $61.18 | $341,078.50 |
DisclosureSEC source: 0001205703-26-000006 · wk-form4_1771880710.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 253,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2026 Filed Feb 23, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 13,093 | $61.76 | $808,623.68 |
DisclosureSEC source: 0001205703-26-000006 · wk-form4_1771880710.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 28,475 | $0.00 Strike: $106.21 | $0.00 |
DisclosureSEC source: 0001205703-26-000002 · wk-form4_1769029605.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,475 Underlying: Common Stock · 28,475 shares Expires 2036-01-15 F1 · derivative.exercise_date: Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 39,471 | $0.00 Strike: $68.25 | $0.00 |
DisclosureSEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,471 Underlying: Common Stock · 39,471 shares Expires 2035-07-14 F5 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 43,846 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,846 Underlying: Common Stock · 43,846 shares Expires 2028-07-15 F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 17,538 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · nonDerivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,800 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 229,661 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,628 | $68.25 | $179,361.00 |
DisclosureSEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,262 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,280 | $69.98 | $89,574.40 |
DisclosureSEC source: 0000879169-25-000086 · wk-form4_1752696353.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,890 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 21:07 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 40,289 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0000879169-25-000035 · wk-form4_1737580032.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,289 Underlying: Common Stock · 40,289 shares Expires 2035-01-16 F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 44,411 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,411 Underlying: Common Stock · 44,411 shares Expires 2034-07-14 F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:28 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 749 | $64.25 | $48,123.25 |
DisclosureSEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · nonDerivative · entry 2 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,170 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 219,502 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:28 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 19,851 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000134 · wk-form4_1721233676.xml · nonDerivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,919 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:31 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 141,011 | Not disclosed Strike: $2.35 | Not disclosed |
DisclosureSEC source: 0000950170-24-068904 · ownership.xml · derivative · entry 5 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 141,011 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:31 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0000950170-24-068904 · ownership.xml · derivative · entry 4 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:31 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0000950170-24-068904 · ownership.xml · derivative · entry 3 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.